Indeed, chemotherapy-induced resistance via CDK4 amplification, RB loss, and cyclin E1 amplification has been suggested to contribute to the lack of efficacy of palbociclib in pancreatic cancer when given as the third or fourth line of treatment (28). This evidence concerns the gene CDK4 and familial pancreatic carcinoma.